WO2010005982A3 - Biomarqueurs multiplexés de résistance à l'insuline - Google Patents

Biomarqueurs multiplexés de résistance à l'insuline Download PDF

Info

Publication number
WO2010005982A3
WO2010005982A3 PCT/US2009/049831 US2009049831W WO2010005982A3 WO 2010005982 A3 WO2010005982 A3 WO 2010005982A3 US 2009049831 W US2009049831 W US 2009049831W WO 2010005982 A3 WO2010005982 A3 WO 2010005982A3
Authority
WO
WIPO (PCT)
Prior art keywords
insulin resistance
aspects
relates
methods
biomarkers
Prior art date
Application number
PCT/US2009/049831
Other languages
English (en)
Other versions
WO2010005982A2 (fr
Inventor
Thomas Wang
Oded Shaham
Robert Gerszten
Vamsi K. Mootha
Vasan S. Ramachandran
Martin Larson
Original Assignee
The General Hospital Corporation
Massachusetts Institute Of Technology
Trustees Of Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation, Massachusetts Institute Of Technology, Trustees Of Boston University filed Critical The General Hospital Corporation
Priority to US13/002,815 priority Critical patent/US20110311650A1/en
Publication of WO2010005982A2 publication Critical patent/WO2010005982A2/fr
Publication of WO2010005982A3 publication Critical patent/WO2010005982A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention, sous certains aspects, porte sur des procédés de caractérisation de troubles métaboliques liés au glucose. Sous certains aspects, l'invention porte sur des procédés et des coffrets utiles pour le diagnostic, la classification, l'évaluation du profil et le traitement de troubles métaboliques liés au glucose. Sous certains aspects, l'invention porte sur des procédés utiles pour le diagnostic, la classification, l'évaluation du profil et le traitement du diabète.
PCT/US2009/049831 2008-07-07 2009-07-07 Biomarqueurs multiplexés de résistance à l'insuline WO2010005982A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/002,815 US20110311650A1 (en) 2008-07-07 2009-07-07 Multiplexed biomarkers of insulin resistance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13415408P 2008-07-07 2008-07-07
US61/134,154 2008-07-07

Publications (2)

Publication Number Publication Date
WO2010005982A2 WO2010005982A2 (fr) 2010-01-14
WO2010005982A3 true WO2010005982A3 (fr) 2010-05-27

Family

ID=41507695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/049831 WO2010005982A2 (fr) 2008-07-07 2009-07-07 Biomarqueurs multiplexés de résistance à l'insuline

Country Status (2)

Country Link
US (1) US20110311650A1 (fr)
WO (1) WO2010005982A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011082433A1 (fr) * 2010-01-04 2011-07-07 Lineagen, Inc. Biomarqueurs de la fonction pulmonaire basés sur la métabolomique
EP2619592A4 (fr) 2010-09-21 2014-05-07 Proteomics Internat Pty Ltd Biomarqueurs associés au pré-diabète, au diabète et aux affections associées au diabète
JP6158186B2 (ja) * 2011-09-14 2017-07-05 メタボロン，インコーポレイテッド インスリン抵抗性に関連するバイオマーカーおよびそれを使用する方法
CN110133299A (zh) * 2012-03-18 2019-08-16 株式会社资生堂 疾病样品分析装置、分析系统及分析方法
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9470771B2 (en) 2012-06-08 2016-10-18 Liposcience, Inc. NMR measurements of NMR biomarker GlycA
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
JP6404834B2 (ja) * 2013-01-31 2018-10-17 メタボロン，インコーポレイテッド インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法
KR102204498B1 (ko) * 2013-04-09 2021-01-19 아지노모토 가부시키가이샤 생활습관병 지표의 평가 방법, 생활습관병 지표 평가 장치, 생활습관병 지표 평가 방법, 생활습관병 지표 평가 프로그램 제품, 생활습관병 지표 평가 시스템, 및 정보통신 단말장치
KR20170002318A (ko) * 2015-06-29 2017-01-06 고려대학교 산학협력단 대사체 분석을 이용한 당뇨병 조기 진단용 조성물
JP6873490B2 (ja) * 2015-10-18 2021-05-19 ジア，ウェイ 糖尿病関連バイオマーカーおよび糖尿病関連状態の処置
CN106979982B (zh) * 2016-01-19 2021-01-05 上海市第六人民医院 一种用于糖尿病风险预测、治疗评价的方法及试剂盒
EP3901631A3 (fr) * 2017-08-17 2021-12-29 Société des Produits Nestlé S.A. Marqueurs dans la prépuberté pour le prédiabète chez l'enfant
CN108459157B (zh) * 2018-01-11 2020-11-27 中国药科大学 一种预测伊立替康化疗毒性生物标志物的组合物
CN112326948B (zh) * 2020-11-09 2023-08-11 上海市内分泌代谢病研究所 用于预测糖尿病的生物标记物、试剂盒及其使用方法
CN112946117A (zh) * 2021-02-01 2021-06-11 黑龙江中医药大学 用于早期诊断多囊卵巢综合征患者合并代谢综合征的代谢标志物及用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070178548A1 (en) * 2003-11-28 2007-08-02 Giorgio Ricci Method for quantitative and semi-quantitative detection of l-phenylalanine, l-tyrosine, l-3,4-dihydroxyphenylalanine and their corresponding keto-acids, phenylpiruvic acid, 3-hydroxyphenylpyruvic acid and 3,4-dihydroxyphenylpyruvic acid in biological fluids, related kits for diagnosis and monitoring of altered metabolisms of these aminoacids
US20070218561A1 (en) * 2004-10-12 2007-09-20 Quest Diagnostics Investments Incorporated Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry
US20070218519A1 (en) * 2005-10-11 2007-09-20 Tethys Bioscience, Inc. Diabetes-associated markers and methods of use thereof
EP1837657A1 (fr) * 2006-03-24 2007-09-26 Metanomics GmbH Moyens et procédé pour prédire ou diagnostiquer un diabète

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070178548A1 (en) * 2003-11-28 2007-08-02 Giorgio Ricci Method for quantitative and semi-quantitative detection of l-phenylalanine, l-tyrosine, l-3,4-dihydroxyphenylalanine and their corresponding keto-acids, phenylpiruvic acid, 3-hydroxyphenylpyruvic acid and 3,4-dihydroxyphenylpyruvic acid in biological fluids, related kits for diagnosis and monitoring of altered metabolisms of these aminoacids
US20070218561A1 (en) * 2004-10-12 2007-09-20 Quest Diagnostics Investments Incorporated Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry
US20070218519A1 (en) * 2005-10-11 2007-09-20 Tethys Bioscience, Inc. Diabetes-associated markers and methods of use thereof
EP1837657A1 (fr) * 2006-03-24 2007-09-26 Metanomics GmbH Moyens et procédé pour prédire ou diagnostiquer un diabète

Also Published As

Publication number Publication date
WO2010005982A2 (fr) 2010-01-14
US20110311650A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
WO2010005982A3 (fr) Biomarqueurs multiplexés de résistance à l'insuline
WO2010037859A3 (fr) Méthodes permettant de prédire ou contrôler si un patient affecté d’un cancer répond à un traitement par une molécule de la famille des taxoïdes
WO2009111595A9 (fr) Diagnostic et surveillance de troubles dépressifs basés sur une pluralité de panels de biomarqueurs
WO2009043051A3 (fr) Molécules se fixant au cd23 et leurs méthodes d'utilisation
MX2010000414A (es) Biomarcadores para prediabetes, enfermedades cardiovasculares y otros trastornos relacionados con sindrome metabolico, y metodos de uso de los mismos.
WO2013066369A3 (fr) Procédés de détection de maladie du greffon contre l'hôte
WO2009083950A3 (fr) Biomarqueurs pour prévoir l'apparition d'une lésion rénale
EP1984726A4 (fr) Procedes, melanges, kits et compositions appartenant à une determination de substances a analyser
WO2010129934A3 (fr) Méthodes et compositions pour le diagnostic d'affections thyroïdiennes
WO2010068686A3 (fr) Procédés de diagnostic et prédiction d'une maladie rénale
EP2454587A4 (fr) Dispositifs, procédés et coffrets pour déterminer des concentrations d'analyte
WO2008097277A3 (fr) Expression tcl1 dans la leucémie lymphocytaire chronique (llc) régulée par mir-29 et mir-181
EP2118772A4 (fr) Méthode d'établissement de profils protéomiques pour le diagnostic et la surveillance d'états pathologiques, le criblage de compositions et la surveillance thérapeutique
WO2010019566A3 (fr) Procédés de détermination de taux de 1,25 dihydroxy vitamine d2 et d3
WO2009152521A3 (fr) Dépistage de troubles neurodégénératifs
WO2008129296A3 (fr) Marqueurs de maladies
WO2010045490A3 (fr) Mappage sur hyperespace multidimensionnel de biomarqueur humain pour des troubles dépressifs
WO2007134028A3 (fr) Biomarqueurs pour la dépression et méthodes d'utilisation de ceux-ci
EP2319937A4 (fr) Méthode de mesure des composants sanguins utilisant du sang total hémolysé, et kit associé
WO2009120801A3 (fr) Thérapies inhibitrices d’ikki et procédés de criblage, et diagnostics d’ikki apparentés
WO2009096181A3 (fr) Procédé d'amorçage sécurisé avec composants facultatifs
WO2009150255A3 (fr) Marqueurs destinés à prédire la réponse et la survie de patients traités anti-egfr
WO2006085121A3 (fr) Biomarqueurs et leurs utilisations
WO2009103843A3 (fr) Méthode et dispositif de détection d'un analyte
WO2008065682A3 (fr) Variantes génétiques de susceptibilité au diabète mellitus de type 2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09795076

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09795076

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13002815

Country of ref document: US